MoodMark Dx
Diagnosis of Major Depressive Disorder
ResearchActive
Key Facts
About Pax Neuroscience
Pax Neuroscience is a private, pre-revenue diagnostics company targeting the massive and underserved depression market. Its core asset is the MoodMark® platform, a biomarker-based assay that measures Gsalpha protein localization in blood cells to provide objective diagnostic and treatment response data. The company has secured approximately $1.8 million in non-dilutive funding from the National Institute of Mental Health (NIMH) via SBIR/STTR grants to validate its technology. Pax aims to serve both clinical depression management and pharmaceutical R&D, addressing a critical need for precision in psychiatric care.
View full company profile